Company intelligence / Profile preview
Roca Therapeutics
- Ownership
- Private
- Development stage
- Preclinical
Overview
Roca Therapeutics is developing first-in-class, non-invasive small molecule therapies for severe ocular diseases. Their lead candidate, RCT001, targets metastatic uveal melanoma and aims to address disease mechanisms involving resistant angiogenesis and immunosuppressive inflammation. A second candidate is being developed for neovascular glaucoma associated with uveal melanoma. The company has completed a seed funding round to advance its programs toward IND/CTA readiness
- Therapeutic areas
- OncologyOphthalmology
- Modalities
- Small molecules
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Roca Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Roca Therapeutics.